
A surge in demand for weight loss drug Ozempic has helped Novo Nordisk post a 25% jump in revenues in the first half of the year, the Danish company said today.
The Bagsværd-based pharma giant said it had seen a 48% rise in sales of its Ozempic treatment in the US, and a near one-third rise in sales worldwide, to hit 56 billion Danish Krone (£6.5 billion).